Interleukin-6 serum levels are associated with disease features and cardiovascular risk in patients with systemic sclerosis

被引:0
作者
Ibrahim-Achi, Z. [1 ]
de Vera-Gonzalez, A. [2 ]
Gonzalez-Delgado, A. [2 ]
Lopez-Mejias, R. [3 ]
Gonzalez-Gay, M. A. [3 ,4 ,5 ]
Ferraz-Amaro, I. [6 ,7 ]
机构
[1] Hosp Univ Canarias, Div Angiol & Vasc Surg, Tenerife, Spain
[2] Hosp Univ Canarias, Div Cent Lab, Tenerife, Spain
[3] IDIVAL, Epidemiol Genet & Atherosclerosis Res Grp Syst Inf, Santander, Spain
[4] IIS Fdn Jimenez Diaz, Div Rheumatol, Ave los Reyes Catolicos 2, Madrid 28040, Spain
[5] Univ Cantabria, IDIVAL, Santander, Spain
[6] Univ La Laguna ULL, Dept Internal Med, Tenerife, Spain
[7] Hosp Univ Canarias, Div Rheumatol, Tenerife 38320, Spain
关键词
systemic sclerosis; scleroderma; interleukin-6; SCORE2; CORONARY-HEART-DISEASE; TOCILIZUMAB; RECEPTOR; TRIALS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Systemic sclerosis (SSc) is a chronic multisystem disease characterised by microcirculatory vascular dysfunction and progressive fibrosis of the skin and internal organs. Interleukin-6 (IL-6) is a proinflammatory cytokine that has been implicated in the pathogenesis of several autoimmune diseases and in the initiation and progression of the cardiovascular disease. In the present work we aimed to study the relationship of IL-6 with clinical manifestations and the cardiovascular risk in patients with SSc. Methods We carried out a cross-sectional study that included 53 individuals with SSc. A multivariate analysis was performed to study the relationship between IL-6 and disease characteristics and cardiovascular risk assessed by Systematic Coronary Risk Estimation (SCORE2) in SSc. Results The presence of digital ulcers, calcinosis, and anti-Scl70 antibody was associated with higher levels of IL-6. This was also the case for functional respiratory parameters where this association was found to be significant and negative after correction for covariates. In addition, the SCORE2 cardiovascular risk algorithm showed a positive and significant association with circulating IL-6. Conclusion IL-6 levels are associated with disease manifestations and cardiovascular risk in patients with SSc.
引用
收藏
页码:1564 / 1570
页数:7
相关论文
共 50 条
  • [31] Relationship between interleukin-6 and cardiac involvement in systemic sclerosis
    Jurisic, Zrinka
    Martinovic-Kaliterna, Dusanka
    Marasovic-Krstulovic, Daniela
    Perkovic, Dijana
    Tandara, Leida
    Salamunic, Ilza
    Carevic, Vedran
    RHEUMATOLOGY, 2013, 52 (07) : 1298 - 1302
  • [32] RELATIONSHIP BETWEEN INTERLEUKIN-6 AND CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS
    Juricic, Z.
    Martinovic-Kaliterna, D.
    Krstulovic-Marasovic, D.
    Perkovic, D.
    Carevic, V.
    Morovic-Vergles, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S34 - S34
  • [33] Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis
    Taniguchi, Takashi
    Asano, Yoshihide
    Fukasawa, Takemichi
    Yoshizaki, Ayumi
    Sato, Shinichi
    JOURNAL OF DERMATOLOGY, 2017, 44 (08) : 967 - 971
  • [34] Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease
    Tomcik, Michal
    Zerr, Pawel
    Palumbo-Zerr, Katrin
    Storkanova, Hana
    Hulejova, Hana
    Spiritovic, Maja
    Kodet, Ondrej
    Stork, Jiri
    Becvar, Radim
    Vencovsky, Jiri
    Pavelka, Karel
    Filkova, Maria
    Distler, Joerg H. W.
    Senolt, Ladislav
    RHEUMATOLOGY, 2015, 54 (12) : 2273 - 2282
  • [35] The Role of Plasma Interleukin-6 Levels on Atherosclerotic Cardiovascular Disease and Cardiovascular Mortality Risk Scores in Java']Javanese Patients with Chronic Kidney Disease
    Susilo, Hendri
    Thaha, Mochammad
    Pikir, Budi Susetyo
    Alsagaff, Mochamad Yusuf
    Suryantoro, Satriyo Dwi
    Wungu, Citrawati Dyah Kencono
    Pratama, Nando Reza
    Pakpahan, Cennikon
    Oceandy, Delvac
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (07):
  • [36] Elevated serum interleukin-6 levels in patients with pancreatic cancer
    Okada, S
    Okusaka, T
    Ishii, H
    Kyogoku, A
    Yoshimori, M
    Kajimura, N
    Yamaguchi, K
    Kakizoe, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1998, 28 (01) : 12 - 15
  • [37] INTERLEUKIN-6 SERUM LEVELS IN PATIENTS WITH MULTIPLE-MYELOMA
    EMILE, C
    FERMAND, JP
    DANON, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (02) : 439 - 440
  • [38] INCREASED SERUM INTERLEUKIN-6 LEVELS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    HEROLD, M
    SCHMALZL, F
    ZWIERZINA, H
    LEUKEMIA RESEARCH, 1992, 16 (6-7) : 585 - 588
  • [39] Serum interleukin-6 and -10 levels in patients with gastric cancer
    Masahide Ikeguchi
    Tomoko Hatada
    Manabu Yamamoto
    Takanori Miyake
    Tomonori Matsunaga
    Youji Fukumoto
    Yoshinori Yamada
    Kenji Fukuda
    Hiroaki Saito
    Shigeru Tatebe
    Gastric Cancer, 2009, 12 : 95 - 100
  • [40] Preoperative Levels of Serum Interleukin-6 in Patients with Hepatocellular Carcinoma
    Pang, Xiong-Hao
    Zhang, Jing-Ping
    Zhang, Yao-Jun
    Yan, Jing
    Pei, Xiao-Qing
    Zhang, Ya-Qi
    Li, Jin-Qing
    Zheng, Limin
    Chen, Min-Shan
    HEPATO-GASTROENTEROLOGY, 2011, 58 (110) : 1687 - 1693